OP009 Long-term safety and efficacy of golimumab in patients with moderately to severely active ulcerative colitis: Results from the PURSUIT-SC Maintenance study extension
Walter Reinisch(Medical University of Vienna), P. Rutgeerts, Brian G. Feagan(Western University), Colleen Marano(Johnson & Johnson (United States)), J.-F. Colombel, Lakshmi Padgett(Janssen (United States)), H. Zhang(Hôpital Beaujon), Richard Strauss, Judith Collins(Oregon Health & Science University), William J. Sandborn(University of San Diego), Jewel Johanns(Johnson & Johnson (United States)), Peter G. Gibson(University Gastroenterology)
Cited by 2
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k